About Repinex2020-08-25T16:17:12+00:00

HEALTHCARE PROFESSIONALS
RepNewBanner

About Repinex XL

Welcome to repinex.co.uk

Repinex XL® is a prolonged-release tablet of ropinirole indicated for the treatment of Parkinson’s disease under the following conditions:1

  • Initial treatment as monotherapy, in order to delay the introduction of levodopa
  • In combination with levodopa, over the course of the disease, when the effect of levodopa wears off or becomes inconsistent and fluctuations in the therapeutic effect occur (“end of dose” or “on-off” type fluctuations).

Available as:

  • 2mg prolonged-release tablets

  • 4mg prolonged-release tablets

  • 8mg prolonged-release tablets

Repinex XL is bioequivalent to Requip® (ropinirole) XL tablets (GlaxoSmithKline, Brentford, UK)2

Repinex XL could offer significant cost savings to your practice and clinical commissioning group (CCG).

Ropinirole 2mg, 4mg and 8mg prolonged-release tablets are in category C of the UK Drug Tariff.3

However, the NHS could make 50% savings on the cost of category C ropinirole by prescribing Repinex XL by brand name.3*

Quite simply a wholesale switch of ropinirole 2mg, 4mg and 8mg prolonged-release prescriptions to Repinex XL could still save an average CCG £15,759 per year.4**

Repinex XL is one of Aspire Pharma’s cost saving prolonged-release products.

In addition Repinex XL:

  • Available from mainline wholesalers;

  • High level of stockholdings;

  • Bioequivalent to the originator brand;2

  • Price guaranteed***

*50% saving on the cost of Category C ropinirole prolonged-release tablets in the UK Drug Tariff. **Savings based on market data in reference 4. Savings calculated from 2019 spend for 218 CCGs switching their generic and originator brand 2,4 and 8mg ropinirole prolonged-release tablet prescriptions to Repinex XL. ***No change in price subject to no material change to the products or Category C of the UK Drug Tariff until the 2024 PPRS review.
References: 1) Repinex XL SmPCs. 2) Data on file. 1010067149 v 4.0 October 2019. 3) February 2020 UK Drug Tariff. 4) epact data Nov 2018 – Nov 2019 (UK)

TRUSTED BRANDS.
DEPENDABLE SUPPLY CHAIN.

For further information please call: 01730 231148,
email: info@aspirepharma.co.uk or visit www.aspirepharma.co.uk
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard.
Adverse events should also be reported to Aspire Pharma Ltd on 01730 231148

For more information about Repinex XL, please see the abbreviated prescribing information.

Revision reference – Repinex XL_19_25.08.2020

More products available
in this range:
Click to view their
individual websites